What is VolitionRx?
VolitionRx operates within the burgeoning field of life sciences, with a core focus on developing advanced diagnostic tests. Leveraging the science of Nucleosomics, the company aims to detect diseases, including cancer, through the analysis of nucleosomes in bodily fluids. This approach seeks to provide a less invasive and more accessible diagnostic pathway compared to current methods. The company's research and development efforts are primarily based in Belgium, with strategic plans for market entry first in Europe, followed by the U.S. and global expansion. The enterprise-level funding suggests a company poised for significant scaling and market penetration.
How much funding has VolitionRx raised?
VolitionRx has raised a total of $5.7M across 3 funding rounds:
Debt
$1.2M
Debt
$500K
Other Financing Round
$4M
Debt (2017): $1.2M with participation from SOFINEX
Debt (2019): $500K led by Texas A&M SOFINEX
Other Financing Round (2021): $4M supported by Namur Invest
Key Investors in VolitionRx
Namur Invest
Namur Invest is a financial partner for businesses in the Namur province, offering a variety of financing solutions tailored to meet their needs and strengthen their financial structure for the medium and long term. The company, a public-private partnership, funds projects that demonstrate development potential and create added value.
SOFINEX
SOFINEX is an entity involved in providing financing, likely focusing on strategic investments and capital for businesses. Their involvement suggests a role in supporting the growth and operational capacity of companies within their investment scope.
Texas A&M SOFINEX
Texas A&M SOFINEX appears to be a financial entity, possibly related to institutional investment or a specific fund, contributing capital to companies. Their participation indicates a strategic interest in the life sciences sector.
What's next for VolitionRx?
With the recent major strategic investment and substantial total funding, VolitionRx is positioned to advance its product development pipeline and expand its market reach. The company's focus on bringing its diagnostic products to market, initially in Europe and then globally, indicates a clear growth strategy. Future developments will likely involve regulatory approvals, clinical validation, and the establishment of robust commercialization channels. The ongoing investment signifies confidence in VolitionRx's Nucleosomics technology and its potential to revolutionize disease diagnostics, moving towards a future where early detection is more accessible and routine.
See full VolitionRx company page
